Wed, Jan 28, 2015, 3:03 PM EST - U.S. Markets close in 57 mins.

Recent

% | $
Quotes you view appear here for quick access.

Coronado Biosciences, Inc. Message Board

galaberge 32 posts  |  Last Activity: Jan 27, 2015 2:24 PM Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Looks like news coming. Hope you are not short.

    by schroe_us Jan 26, 2015 11:10 PM
    galaberge galaberge Jan 27, 2015 2:24 PM Flag

    Scope of the problem: Multi-drug resistant gonorrhea would have substantial health and economic consequences in the United States. First, there would be an increase in gonorrhea in the population because people with gonorrhea will remain infectious for a longer period of time. This increase in gonorrhea would lead to increases in PID in women and epididymitis in men. Second, because gonorrhea can facilitate the acquisition and transmission of HIV, the increase in gonorrhea prevalence could lead to increases in new HIV infections as well. Impact Multi-drug resistant gonorrhea increases the economic burden on the entire healthcare system since resistant infections cost more to treat and can prolong healthcare use. Modeling studies suggest that gonorrhea prevalence in the population could increase by 7% to 40% per year as a result of antimicrobial resistance developing in a population without additional therapies, and these increases could last for about seven years before leveling off. Gonorrhea rates seven years after onset of antimicrobial resistance would be 4.3 times higher than they are now. Over 7 years, there would be an additional 5.9 million cases of gonorrhea as a result of drug resistance.
    Costs of the additional gonorrhea cases:
    The additional 5.9 million cases of untreatable gonorrhea would result in 255,000 cases of PID in women (which includes about 51,000 cases of tubal-factor infertility) at a cost of $585 million

  • IRVINE, Calif., Jan. 21, 2015 /PRNewswire/ -- Netlist, Inc. (NLST) announced today that the Examiner in the consolidated reexamination of U.S. Pat. No. 7,619,912 ("'912 Patent") issued an Answer maintaining the patentability of 92 claims related to LRDIMM. The reexaminations were brought in the United States Patent and Trademark Office (USPTO) by Google Inc., Inphi Corporation, and SMART Modular Technologies.

    Sentiment: Strong Buy

  • Reply to

    OK - ABOUT HAD ENUF OF THIS BS 1.5-1.6 RANGE

    by vivaespana11 Jan 15, 2015 12:02 PM
    galaberge galaberge Jan 16, 2015 2:49 PM Flag

    Patience is all what we need. Within several months we will be in a very good position. Just wait and see. In the mean time why don't you buy other interesting stocks to have more fun in investing ?

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    ALT increase in 4.6% of subjects

    by btech_g Jan 16, 2015 7:11 AM
    galaberge galaberge Jan 16, 2015 2:25 PM Flag

    You are spot on. The key words are "REVERSIBLE",and "BOTH TREATMENTS". There is absolutely no dangers with this very small temporary ALT elevation.

    Long and strong CEMP

    Sentiment: Strong Buy

  • Reply to

    JP Morgan Conference

    by mdr0418 Jan 5, 2015 12:15 PM
    galaberge galaberge Jan 5, 2015 12:23 PM Flag

    Thanks for sharing your intel. As usual you are well informed because you call the IR a thing everyone should do.

    2015 will be THE year of SYN.

    Long an strong SYN

    Sentiment: Strong Buy

  • Reply to

    Delivery on Promises

    by mdr0418 Dec 22, 2014 10:52 AM
    galaberge galaberge Dec 29, 2014 7:44 AM Flag

    If you want to post here, post about something of substance about the company or its market. Otherwise, you're nothing but a useless internet troll.

    Sentiment: Strong Buy

  • ....held by the Infectious Diseases Society of America (IDSA), October 8-12, in Philadelphia, PA.

    I quote :

    "•SYN-004 differs from its parent enzyme, P1A, by one amino acid, D276N

    •SYN-004 displayed improved degradation of a panel of cephalosporin, including ceftriaxone

    •Manufacturing of SYN-004was optimized to obtain high yields with simplified purification

    •Enteric-coatedSYN-004pellets are inert at low pH and rapidly dissolute at pH’s 5.5

    •Enteric-coated SYN-004 pellets rapidly dissolute in human chime and display stable activity for
    at least 4 hours

    •In dogs, oral delivery of SYN-004 pellets resulted in efficient degradation of intestinal CRO

    •Clinical evaluation of SYN-004 is anticipated in to begin in late 2014"

    See the link for the poster : " idsaDOTconfexDOTcom/idsa/2014/webprogram/Paper46546.html "

    So we should have in few days the positive results of the Phase 1a and 1b

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Dec 14, 2014 11:14 PM Flag

    Ugt - Nice post. Well summarized. Now let's hope Riley will take few minutes to read our posts and brings some clarification in order to maintain the PPS stable and coherent with our pipeline.

    Long and strong SYN

    Sentiment: Strong Buy

  • What a loss of time from your part. The truth will always prevail with the longs. Have a nice evening...with your thumbs down !!!!

    Sentiment: Strong Buy

  • galaberge galaberge Dec 14, 2014 1:36 PM Flag

    Riley as a CEO said something on the 14th November 2014 to an analyst who will follow his performance and may have a great influence on the SYN's stock. 2 weeks later Riley is saying a complete different story : 40 person instead of 12-20, and 1a by year-end instead of 1a AND 1b by year-end ! When a CEO is saying lies in a 2 weeks period, he lost his credibility.

    Also where do you take the fact that 1b will be at the end of January to early Feb 2015? I have learnt to be honest and this kind of behaviour from Riley undermines his credibility and gives ammunitions for the bashers.

    Sentiment: Strong Buy

  • galaberge galaberge Dec 14, 2014 1:03 PM Flag

    It's another thing why Riley has lost confidence from the future buyers and the actual shareholders ! The phase 1a AND 1b were due BY YEAR-END 2014 as per the follwing answer to a question of an analyst. I quote :

    "Daryl Weber - Wells Fargo Advisors, LLC.
    Good morning, gentlemen. So a couple of questions here; with respect to your Phase 1 and Phase 1a and Phase 1b for C. diff; how many patients are you anticipate enrolling? And the top line data you will be reporting by year end, now what would that entail? And will it be for all the patient cohort? Thank you.

    Jeff Riley - President and CEO
    Thanks for the questions, Daryl. To answer your first question the Phase 1a and 1b will be between 12 and 20 patients. We’re looking for safety in these, and obviously we’re doing a dose response as well. These are in normal patients and these are very, very quick studies. Really look and see what's happening in both genetically as well as PK/PD profiles of these patients. And as we said, we should have data from that by the end of this year."

    See the link : "Synthetic Biologics' (SYN) CEO Jeff Riley on Q3 2014 Results - Earnings Call Transcript "

    Sentiment: Strong Buy

  • Based on the PR of SYN we should get !a AND 1b before year-end 2014. Check the link :" syntheticbiologicsDOTcom/2014-11-24-Synthetic-Biologics-Safe-to-Proceed-Under-IND-to-Initiate-Clinical-Trials-of-SYN-004-for-the-Prevention-C-difficile-Infection "

    Sentiment: Strong Buy

  • Phase 1

    The initial phase of testing of an investigational drug in humans. Usually a hase 1 clinical study is conducted in a small number of healthy volunteers or patients with a disease for which the drug may be useful. Generally, the study is designed to determine the side effects of the drug and its pharmacokinetics. Some information regarding drug efficacy may be collected if patients with a disease participate. A phase frequently encompasses more than one clinical trial.

    Phase 1 sometimes is sub-divided into Phases 1a and 1b, for example when the first set of Phase 1 trials (Phase 1a) is performed in healthy volunteers and a second set of Phase 1 trials (Phase 1b) is performed in patients with a disease.

    Check the following link : " bloomingrosefoundationDOTorg/wp-content/uploads/2009/10/Glossary-of-Clinical-Trials-TermsDOTpdf "

    So we will have efficay results for patients with the C.Difficile disease.

    Long and strong SYN

    Sentiment: Strong Buy

  • The oral enzyme candidate SYN-004 is intended to protect the GI tract from the overgrowth of C. difficile. Watch the full video to learn more! :" youtubeDOTcom/watch?v=jvnH_Yipo1c "

    Sentiment: Strong Buy

  • Don't eat too much turkey and listen to alot of football

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Nov 24, 2014 6:22 PM Flag

    To answer your question here is what SYN has written on their website :

    I quote :

    "Anticipating a 505(b)(2) regulatory pathway for SYN-010, a corporate Investigational New Drug (IND) application is expected to be filed with the FDA in the first quarter of 2015 with the initiation of a Phase 2 clinical trial of SYN-010 in C-IBS anticipated in the first half of 2015"

    2015 will be THE year of Synthetic Biologics !

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Nov 24, 2014 8:40 AM Flag

    They just say again "Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end."

    So I have no doubt we will have the results soon.

    Long and strong SYN

    Sentiment: Strong Buy

  • Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.

    "We are pleased the FDA completed the 30-day review of our IND and to be initiating clinical trials of the first potential point-of-care preventative therapy for C. difficile, the CDC's top-ranking public health threat," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "Taking immediate and aggressive action to develop a therapy that can prevent C. difficile before it starts is critical in addressing this pervasive and life-threatening infection, and IND activation for SYN-004 is a key step toward the development and eventual commercialization of therapy to protect the millions of at risk U.S. patients."

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Nov 18, 2014 2:20 PM Flag

    I think it will go to 1 cent ! Is it enough for you id..#$%$ ?

    Long and strong SYN

    Sentiment: Strong Buy

  • Here is the link :

    "seekingalphaDOTcom/article/2683225-synthetic-biologics-syn-ceo-jeff-riley-on-q3-2014-results-earnings-call-transcript?app=1&uprof=44"

    Long and strong SYN

    Sentiment: Strong Buy

CNDO
2.3805-0.0795(-3.23%)2:49 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.